Skip to main content
. 2022 Sep 15;81(12):1661–1668. doi: 10.1136/ard-2022-222630

Figure 3.

Figure 3

Efficacy results during the double‐blind treatment period (ITT population). ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; DAS28 (CRP), Disease Activity Score 28 based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; ITT, intention-to-treat; OKZ, olokizumab; PBO, placebo; q2w, every 2 weeks; q4w, every 4 weeks.